Prostate Cancer Gene-Edited Cell Lines for Drug Discovery

Prostate cancer is the second most frequently diagnosed cancer in men worldwide, with an estimated 1.4 million new cases and 375,000 deaths in 2020 (WHO GLOBOCAN). In the United States, the lifetime risk of developing prostate cancer is approximately 1 in 8, and it remains the leading cause of cancer death among men after lung cancer (NCI SEER). The 5-year survival rate for localized disease is nearly 100%, but for metastatic disease it drops to about 30% (NCI). Key risk factors include age, family history, African ancestry, and genetic mutations (e.g., BRCA2, HOXB13).

Prostate cancer is ideal for mechanistic studies due to its well-characterized subtypes (e.g., AR-dependent, AR-independent, neuroendocrine), extensive public genomic datasets (TCGA, COSMIC), and the availability of robust cell lines (LNCaP, PC3, DU145, VCaP). Open questions include mechanisms of castration resistance, lineage plasticity, and immune evasion. Gene-edited cell models allow precise dissection of these pathways.

Prostate cancer development involves several key pathways:

1. Androgen Receptor (AR) Signaling:

• • Androgen binding activates AR, which translocates to the nucleus and drives transcription of growth-promoting genes.
• • In castration-resistant prostate cancer (CRPC), AR is reactivated via amplification, mutation, or splice variants (e.g., AR-V7).

2. PI3K/AKT/mTOR Pathway:

• • PTEN loss (40-60% of primary tumors) leads to PI3K activation, promoting cell survival and proliferation.
• • AKT phosphorylation drives downstream mTOR signaling.

3. DNA Damage Repair:

• • Mutations in BRCA1/2, ATM, and other homologous recombination repair genes occur in 20-30% of metastatic cases.
• • These defects create vulnerability to PARP inhibitors.

4. Cell Cycle and Apoptosis:

• • TP53 mutations (20-30% of CRPC) and RB1 loss contribute to genomic instability and lineage plasticity.

Data from TCGA (Cancer Genome Atlas) and COSMIC (Catalogue of Somatic Mutations in Cancer).

Key deregulated networks include:

• • Wnt/β-catenin: β-catenin stabilization (via CTNNB1 mutation or APC loss) drives transcription of MYC and CCND1.
• • MAPK/ERK: RAS mutations (KRAS, NRAS) are rare in primary tumors but occur in 5-10% of metastases.
• • TGF-β: Dual role; early tumor suppression lost via SMAD4 deletion, later promotes metastasis.
• • NF-κB: Constitutive activation in CRPC via IKK complex, promoting inflammation and survival.

Key nodes for gene editing: PTEN, TP53, AR, RB1, CHD1.

Organoids derived from patient tumors retain stromal interactions and drug response heterogeneity, offering advantages over 2D cultures for preclinical testing.

• • Patient-Derived Xenografts (PDX): Implantation of human tumor fragments into immunodeficient mice; preserve tumor heterogeneity and drug response.
• • Genetically Engineered Mouse Models (GEMM): Conditional knockout of Pten and Trp53 in prostate epithelium (e.g., PB-Cre4) recapitulates CRPC.
• • Induced Models: Testosterone-induced prostate cancer in rats; less common.
• • Xenograft with gene-edited cells: Injection of CRISPR-modified human cell lines (e.g., LNCaP with AR knockout) into mice for in vivo functional studies.

CRISPR/Cas9 technology enables the generation of isogenic cell lines with precise genetic modifications. Examples include:

• • TP53 knockout in LNCaP cells to study loss of tumor suppression.
• • PTEN deletion in DU145 cells to model PI3K pathway activation.
• • AR-V7 knock-in in 22Rv1 cells to investigate castration resistance.
• • KRAS G12D knock-in in PC3 cells for MAPK pathway studies.

Commercially available, sequence-verified knockout and knock-in models (e.g., TP53-/-, PTEN-/-, AR knockout) accelerate research by eliminating the need for in-house editing and validation. These models are used for target validation, drug screening, and mechanistic studies.

CRISPR knockout and knock-in cell lines are essential for validating candidate oncogenes and tumor suppressors. For example:

• • Knockout of AR in LNCaP cells confirmed its role in androgen-dependent growth.
• • Knock-in of SPOP mutants in benign prostate cells induced transformation.
• • PTEN knockout in DU145 cells increased AKT phosphorylation and invasion.

These models provide causal evidence for gene function in a controlled genetic background.

Isogenic pairs (e.g., PTEN wild-type vs. knockout) enable high-throughput screening for compounds that selectively target mutant cells. Examples:

• • PTEN-null cells show sensitivity to PI3K inhibitors (e.g., GDC-0941).
• • TP53 knockout cells are resistant to DNA-damaging agents like cisplatin.
• • AR-V7 knock-in models are used to screen for inhibitors of constitutive AR signaling.

Resistance mechanisms can be studied by exposing gene-edited cells to drugs and sequencing surviving clones.

CRISPR synthetic lethality screens identify genes that become essential in specific genetic backgrounds. For example:

• • In PTEN-null cells, loss of CHD1 or MED12 is synthetic lethal, suggesting therapeutic targets.
• • In BRCA2-deficient models, PARP1 inhibition is lethal, a principle used in olaparib therapy.
• • Genome-wide CRISPR screens in AR-V7-expressing cells revealed dependency on CDK7 and BRD4.

These findings translate into biomarkers for patient stratification.